FDA Fast Track for Erasca's Pan-RAS Drug in Pancreatic Cancer
ERAS has more than doubled off its 52-week low of $1.33.
Summary
Erasca received FDA Fast Track Designation for ERAS-0015 in metastatic pancreatic adenocarcinoma, a regulatory milestone that could expedite development and review. The company plans three potentially registration-enabling trials across pancreatic and lung cancers, with additional Phase 1 data expected in H1 2027. This follows July's encouraging 57% uORR8wk in 2L+ KRAS G12X pancreatic cancer and a $632.5M follow-on offering that strengthened the balance sheet. The designation validates the program's potential but does not guarantee approval; the ongoing RevMed litigation remains a key risk. Watch for trial initiations and H1 2027 data readouts.
At the time of this announcement, ERAS was trading at $18.11 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.2B. The 52-week trading range was $1.33 to $24.28. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.